ClinicalTrials.gg
CompletedNCT01779791Updated Jul 18, 2017

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

A Phase 2 interventional study of PCI-32765 (Ibrutinib) in Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 54 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-18.

Primary conditionLymphoma, FollicularRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. The study's title name Lymphoma, Follicular, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2016, 10 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ibrutinib in Lymphoma, Follicular — none open to participants now, 7 under way, 1 of them phase 3. ibrutinib · Lymphoma, Follicular.

Enrollment
6th of 24
110 · median 48
Started
2013
with 5 others
Phase 2
10 of 24
none open now
Registered
4th of 24
by date
Lead sponsor
4 of 24
Janssen Research & Development, LLC

Among the 24 studies testing ibrutinib in Lymphoma, Follicular, this one is the 6th largest by enrollment, is one of 6 that started in 2013, is one of 10 in phase 2, and was the 4th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 24 studies testing ibrutinib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing ibrutinib in Lymphoma, Follicular as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).

Read the detailed description

This is an open-label (identity of assigned study drug will be known) study of PCI-32765 (ibrutinib) in approximately 110 patients with chemoimmunotherapy-resistant FL whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. Each patient must have resistant disease to the last therapy (defined as progression of disease [PD] during or within 12 months of the last dose of chemotherapy in a CD20 antibody combination chemotherapy regimen). The study will include the following phases: screening (up to 30 days prior to the first dose of study drug), treatment (until PD or unacceptable toxicity), and posttreatment follow-up (until death, lost to follow up, withdrawal of consent, or study end [defined as 2 years after the last patient is enrolled]). Patients will receive 560 mg of PCI-32765 by mouth once daily on a 21-day cycle. Treatment will be continuous (without interruption) and self-administered at home. The treatment phase will extend from administration of the first dose of study medication until PD or unacceptable toxicity. If a patient who had radiological evidence of PD is clinically stable or improving or exhibiting signs of tumor flare without confirmation of PD by PET or biopsy, they may continue treatment with ibrutinib upon request by the investigator and approval by the sponsor. Posttreatment follow-up will extend from the end of treatment until death, lost to follow up, withdrawal of consent, or study end. Every patient, except for those who explicitly withdraw consent from further site contact, will be followed for survival status until the study ends. In addition, data on subsequent antineoplastic therapy will also be collected. Serial pharmacokinetic samples will be collected and efficacy and safety will be monitored throughout the study. A separate assessment of pharmacokinetics is planned for patients who receive a strong or moderate CYP3A4/5 inhibitor while receiving treatment with ibrutinib. For patients who have already discontinued ibrutinib due to PD, have taken no other anticancer therapy, and now have a radiologically documented delayed response, resumption of ibrutinib is permitted on a case-by-case basis, upon request by the investigator and approval of the sponsor.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Lymphoma
  • Refractory follicular lymphoma
  • Chemoimmunotherapy-resistant follicular lymphoma
  • PCI-32765
  • Ibrutinib
  • IMBRUVICA
04

In context

Lymphoma, Follicular Reclassified

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's enrollment of 110 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic proof of Grade 1, 2, or 3a follicular lymphoma (FL) without clinical or pathological evidence of transformation
  • Previously treated with at least 2 , including at least 1 rituximab combination chemotherapy regimen; last prior line of therapy includes an anti CD20 monoclonal antibody-containing chemotherapy regimen (separate lines of therapy are defined as different regimens that are either separated by disease progression, disease, or relapsed disease)
  • Resistant disease to the last therapy, defined as progression of disease during or within 12 months of the last dose of chemotherapy in a CD20 antibody combination chemotherapy regimen
  • At least 1 measurable site of disease according to International Working Group Revised Response Criteria for Malignant Lymphoma
  • performance status grade 0 or 1
  • Hematology and biochemical laboratory values must be within protocol-defined parameters within 7 days prior to enrollment
  • Agrees to protocol-defined use of effective
  • Women of must have a negative serum or urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other agents within 3 weeks, or major surgery within 4 weeks of first dose of study drug
  • Prior treatment with PCI-32765 or other Bruton's tyrosine kinase inhibitors (patients who progressed or became while on treatment with PI3K inhibitors are excluded)
  • Concurrent enrollment in another therapeutic investigational clinical treatment study
  • Received a prior hematopoietic stem cell transplant (prior autologous hematopoietic stem cell transplant is allowed)
  • Known central nervous system lymphoma
  • History of prior (except malignancy treated with curative intent and with no known active disease present for >=3 years before enrollment, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately treated cervical carcinoma in situ without evidence of disease)
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists
  • Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the Functional Classification
  • Known history of (HIV) or active infection with or active infection with or any uncontrolled active systemic infection requiring intravenous antibiotics
  • Women who are pregnant or breastfeeding
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue risk
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    PCI-32765 (Ibrutinib)

    Drug: PCI-32765 (Ibrutinib)

Interventions

  • 560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.

    Also known as: IMBRUVICA

07

What researchers measure

Primary outcomes

  1. Overall response rate

    Time frame: Up to 2 years after the last patient is enrolled

Secondary outcomes

  1. Duration of response

    Time frame: Every 12 weeks during the first 96 weeks, followed by every 24 weeks thereafter until disease progression (up to 2 years after the last patient is enrolled)

  2. Progression-free survival

    Time frame: Up to progressive disease, death, lost to follow-up, withdrawal of consent, or study end (up to 2 years after the last patient is enrolled)

  3. Overall survival

    Time frame: Up to death, lost to follow-up, withdrawal of consent, or study end (up to 2 years after the last patient is enrolled)

  4. Time to response

    Time frame: Every 12 weeks during the first 96 weeks, followed by every 24 weeks thereafter until disease progression (up to 2 years after the last patient is enrolled)

  5. Number of patients experiencing resolution of lymphoma-related B symptoms

    Time frame: Day 1 of every cycle during the first 12 months, thereafter every other cycle (up to 2 years after the last patient is enrolled)

  6. Number of patients identified with blood biomarkers that alter B-cell receptor signaling or activate alternative signaling pathways

    Time frame: Day 1 of Cycles 1-3, and time of disease progression, or at end-of treatment visit for patients who discontinue treatment without disease progression

  7. Minimum plasma concentration of PCI-32765

    Time frame: Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours

  8. Oral plasma clearance of PCI-32765

    Time frame: Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours

  9. Oral volume of distribution at steady state of PCI-32765

    Time frame: Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours

  10. Area under the plasma-concentration time curve of PCI-32765

    Time frame: Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours

  11. Number of participants affected by an adverse event

    Time frame: Up to 30 days after the last dose of study medication

08

Study locations

54 sites
  • Los Angeles, California, United States
  • Stanford, California, United States
  • Washington, D.C., District of Columbia, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Westwood, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Detroit, Michigan, United States
  • Hackensack, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • New York, New York, United States
  • Greenville, North Carolina, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • Burlington, Vermont, United States
  • Seattle, Washington, United States
  • Adelaide, Australia
  • Concord, Australia
  • Melbourne, Australia
  • Milton, Australia
  • Prahran, Australia
  • Courrière, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Creteil, France
  • Nice Cedex 2, France
  • Nimes Cedex 9, France
  • Paris, France
  • Pessac, France
  • Pierre Benite, France
  • Rennes, France
  • Heidelberg, Germany
  • Köln, Germany
  • Mainz, Germany
  • Ulm, Germany
  • Krakow, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Ekaterinburg, Russian Federation
  • Moscow N/A, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • St-Petersburg, Russian Federation
  • Volgograd, Russian Federation
  • Barcelona, Spain
  • Marbella, Spain
  • Salamanca, Spain
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Southampton, United Kingdom
09

References and documents

Publications

  • Balasubramanian S, Hodkinson B, Schuster SJ, Fowler NH, Trotman J, Hess G, Cheson BD, Schaffer M, Sun S, Deshpande S, Vermeulen J, Salles G, Gopal AK. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer Med. 2022 Jan;11(1):61-73. doi: 10.1002/cam4.4422. Epub 2021 Nov 17. PubMed 34791836 ↗
  • Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31. PubMed 29851546 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in May 2016, 37 months.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 37 months is above that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2013
First posted
Jan 30, 2013
StartActual
Apr 17, 2013
Primary completionActual
May 18, 2016
CompletionActual
May 18, 2016
Last update
Jul 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01779791
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jan 30, 2013
Start date
Apr 17, 2013
Primary completion
May 18, 2016
Completion
May 18, 2016
Last update
Jul 18, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion